← Back to Search

Impact of Suvorexant on Sympathetic Nerve Activity and Baroreflex Function in Chronic Insomnia

Phase 4
Waitlist Available
Led By Jason Carter, PhD
Research Sponsored by Montana State University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 8 week
Awards & highlights
All Individual Drugs Already Approved
Drug Has Already Been Approved
Approved for 5 Other Conditions
Pivotal Trial

Summary

This trial will study whether the drug Suvorexant can help people with chronic insomnia by reducing sympathetic nerve activity and improving baroreflex function.

Eligible Conditions
  • Chronic Insomnia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~8 week
This trial's timeline: 3 weeks for screening, Varies for treatment, and 8 week for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Baroreflex sensitivity
Sympathetic nerve activity
Secondary study objectives
Home sleep quality: Wrist actigraphy
Laboratory sleep quality: Polysomnography
Sympathetic reactivity

Awards & Highlights

All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Drug Has Already Been Approved
The FDA has already approved this drug, and is just seeking more data.
Approved for 5 Other Conditions
This treatment demonstrated efficacy for 5 other conditions.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Drug (Suvorexant)Experimental Treatment1 Intervention
20 mg of Suvorexant daily (taken orally \~1 hour before bedtime)
Group II: PlaceboPlacebo Group1 Intervention
20 mg of Placebo daily (taken orally \~1 hour before bedtime)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Suvorexant
FDA approved

Find a Location

Who is running the clinical trial?

Montana State UniversityLead Sponsor
45 Previous Clinical Trials
1,043,760 Total Patients Enrolled
University of ChicagoOTHER
1,062 Previous Clinical Trials
840,100 Total Patients Enrolled
Jason Carter, PhDPrincipal InvestigatorMontana State University
~5 spots leftby Jan 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top